Snyder Mark Howard has filed 50 insider transactions across 1 company since January 2024.
Most recent transaction: a option exercise of 5332 shares of HALOZYME THERAPEUTICS, INC. ($HALO) on February 20, 2026.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 20, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | Snyder Mark Howard | SVP, CHIEF LEGAL OFFICER | M | Restricted Stock Units | 5332 | $0.00 | 15,995.0000 | 123,904,000 | 25.00% | 0.00% |
| Feb. 20, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | Snyder Mark Howard | SVP, CHIEF LEGAL OFFICER | M | Common Stock | 5332 | $0.00 | 47,257.0000 | 123,904,000 | 12.72% | 0.00% |
| Feb. 23, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | Snyder Mark Howard | SVP, CHIEF LEGAL OFFICER | M | Restricted Stock Units | 7011 | $0.00 | 14,022.0000 | 123,904,000 | 33.33% | 0.01% |
| Feb. 20, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | Snyder Mark Howard | SVP, CHIEF LEGAL OFFICER | F | Common Stock | 2876 | $70.98 | 44,381.0000 | 123,904,000 | 6.09% | 0.00% |
| Feb. 23, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | Snyder Mark Howard | SVP, CHIEF LEGAL OFFICER | M | Common Stock | 7011 | $0.00 | 51,392.0000 | 123,904,000 | 15.80% | 0.01% |
| Feb. 23, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | Snyder Mark Howard | SVP, CHIEF LEGAL OFFICER | F | Common Stock | 3782 | $70.64 | 47,610.0000 | 123,904,000 | 7.36% | 0.00% |
| Feb. 16, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | Snyder Mark Howard | SVP, CHIEF LEGAL OFFICER | F | Common Stock | 6481 | $79.44 | 41,925.0000 | 123,904,000 | 13.39% | 0.01% |
| Feb. 16, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | Snyder Mark Howard | SVP, CHIEF LEGAL OFFICER | F | Common Stock | 2587 | $79.44 | 36,390.0000 | 123,904,000 | 6.64% | 0.00% |
| Feb. 16, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | Snyder Mark Howard | SVP, CHIEF LEGAL OFFICER | M | Common Stock | 4796 | $0.00 | 38,977.0000 | 123,904,000 | 14.03% | 0.00% |
| Feb. 16, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | Snyder Mark Howard | SVP, CHIEF LEGAL OFFICER | M | Performance Stock Units | 12016 | $0.00 | 0.0000 | 123,904,000 | 100.00% | 0.01% |
| Feb. 16, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | Snyder Mark Howard | SVP, CHIEF LEGAL OFFICER | M | Restricted Stock Units | 4796 | $0.00 | 4,796.0000 | 123,904,000 | 50.00% | 0.00% |
| Feb. 16, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | Snyder Mark Howard | SVP, CHIEF LEGAL OFFICER | M | Common Stock | 12016 | $0.00 | 48,406.0000 | 123,904,000 | 33.02% | 0.01% |
| Feb. 9, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | Snyder Mark Howard | SVP, CHIEF LEGAL OFFICER | A | Restricted Stock Units | 17396 | $0.00 | 17,396.0000 | 123,904,000 | 9999.99% | 0.01% |
| Feb. 9, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | Snyder Mark Howard | SVP, CHIEF LEGAL OFFICER | A | Option to Purchase Common Stock | 18730 | $0.00 | 18,730.0000 | 123,904,000 | 9999.99% | 0.02% |
| Feb. 9, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | Snyder Mark Howard | SVP, CHIEF LEGAL OFFICER | A | Performance Stock Units | 29502 | $0.00 | 29,502.0000 | 123,904,000 | 9999.99% | 0.02% |
| Feb. 9, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | Snyder Mark Howard | SVP, CHIEF LEGAL OFFICER | A | Performance Stock Units | 7808 | $0.00 | 45,127.0000 | 123,904,000 | 20.92% | 0.01% |
| Feb. 9, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | Snyder Mark Howard | SVP, CHIEF LEGAL OFFICER | A | Performance Stock Units | 4651 | $0.00 | 12,016.0000 | 123,904,000 | 63.15% | 0.00% |
| Jan. 3, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | Snyder Mark Howard | SVP, CHIEF LEGAL OFFICER | M | Restricted Stock Units | 7611 | $0.00 | 0.0000 | 123,904,000 | 100.00% | 0.01% |
| Jan. 3, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | Snyder Mark Howard | SVP, CHIEF LEGAL OFFICER | M | Common Stock | 7611 | $0.00 | 38,424.0000 | 123,904,000 | 24.70% | 0.01% |
| Jan. 3, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | Snyder Mark Howard | SVP, CHIEF LEGAL OFFICER | F | Common Stock | 4243 | $70.31 | 34,181.0000 | 123,904,000 | 11.04% | 0.00% |
| June 12, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Snyder Mark Howard | SVP, CHIEF LEGAL OFFICER | M | Common Stock | 5035 | $0.00 | 33,524.0000 | 129,424,000 | 17.67% | 0.00% |
| June 12, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Snyder Mark Howard | SVP, CHIEF LEGAL OFFICER | M | Restricted Stock Units | 5035 | $0.00 | 15,102.0000 | 129,424,000 | 25.00% | 0.00% |
| June 12, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Snyder Mark Howard | SVP, CHIEF LEGAL OFFICER | F | Common Stock | 2711 | $54.54 | 30,813.0000 | 129,424,000 | 8.09% | 0.00% |
| Feb. 23, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Snyder Mark Howard | SVP, CHIEF LEGAL OFFICER | M | Restricted Stock Units | 7012 | $0.00 | 21,033.0000 | 129,424,000 | 25.00% | 0.01% |
| Feb. 23, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Snyder Mark Howard | SVP, CHIEF LEGAL OFFICER | F | Common Stock | 3775 | $57.75 | 28,489.0000 | 129,424,000 | 11.70% | 0.00% |
| Feb. 23, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Snyder Mark Howard | SVP, CHIEF LEGAL OFFICER | M | Common Stock | 7012 | $0.00 | 32,264.0000 | 129,424,000 | 27.77% | 0.01% |
| Feb. 20, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Snyder Mark Howard | SVP, CHIEF LEGAL OFFICER | A | Option to Purchase Common Stock | 22603 | $0.00 | 22,603.0000 | 129,424,000 | 9999.99% | 0.02% |
| Feb. 20, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Snyder Mark Howard | SVP, CHIEF LEGAL OFFICER | A | Restricted Stock Units | 21327 | $0.00 | 21,327.0000 | 129,424,000 | 9999.99% | 0.02% |
| Feb. 16, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Snyder Mark Howard | SVP, CHIEF LEGAL OFFICER | M | Common Stock | 17409 | $0.00 | 32,411.0000 | 129,424,000 | 116.04% | 0.01% |
| Feb. 16, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Snyder Mark Howard | SVP, CHIEF LEGAL OFFICER | F | Common Stock | 2582 | $58.29 | 25,252.0000 | 129,424,000 | 9.28% | 0.00% |
| Feb. 16, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Snyder Mark Howard | SVP, CHIEF LEGAL OFFICER | M | Performance Stock Units | 17409 | $0.00 | 0.0000 | 129,424,000 | 100.00% | 0.01% |
| Feb. 16, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Snyder Mark Howard | SVP, CHIEF LEGAL OFFICER | M | Restricted Stock Units | 4796 | $0.00 | 9,592.0000 | 129,424,000 | 33.33% | 0.00% |
| Feb. 16, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Snyder Mark Howard | SVP, CHIEF LEGAL OFFICER | F | Common Stock | 9373 | $58.29 | 23,038.0000 | 129,424,000 | 28.92% | 0.01% |
| Feb. 16, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Snyder Mark Howard | SVP, CHIEF LEGAL OFFICER | M | Common Stock | 4796 | $0.00 | 27,834.0000 | 129,424,000 | 20.82% | 0.00% |
| Feb. 12, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Snyder Mark Howard | SVP, CHIEF LEGAL OFFICER | A | Performance Stock Unit | 7269 | $0.00 | 7,269.0000 | 129,424,000 | 9999.99% | 0.01% |
| Feb. 12, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Snyder Mark Howard | SVP, CHIEF LEGAL OFFICER | A | Performance Stock Units | 30050 | $0.00 | 30,050.0000 | 129,424,000 | 9999.99% | 0.02% |
| Feb. 12, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Snyder Mark Howard | SVP, CHIEF LEGAL OFFICER | A | Performance Stock Units | 6050 | $0.00 | 17,409.0000 | 129,424,000 | 53.26% | 0.00% |
| Feb. 12, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Snyder Mark Howard | SVP, CHIEF LEGAL OFFICER | A | Performance Stock Units | 4698 | $0.00 | 7,365.0000 | 129,424,000 | 176.15% | 0.00% |
| Jan. 3, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Snyder Mark Howard | SVP, CHIEF LEGAL OFFICER | M | Common Stock | 7611 | $0.00 | 19,291.0000 | 129,424,000 | 65.16% | 0.01% |
| Jan. 3, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Snyder Mark Howard | SVP, CHIEF LEGAL OFFICER | M | Restricted Stock Units | 7611 | $0.00 | 7,611.0000 | 129,424,000 | 50.00% | 0.01% |
| Jan. 3, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Snyder Mark Howard | SVP, CHIEF LEGAL OFFICER | F | Common Stock | 4289 | $47.74 | 15,002.0000 | 129,424,000 | 22.23% | 0.00% |
| June 12, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | Snyder Mark Howard | SVP, CHIEF LEGAL OFFICER | A | Restricted Stock Units | 20137 | $0.00 | 20,137.0000 | 134,197,000 | 9999.99% | 0.02% |
| Feb. 23, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | Snyder Mark Howard | SVP, GENERAL COUNSEL | A | Option to Purchase Common Stock | 29064 | $0.00 | 29,064.0000 | 134,197,000 | 9999.99% | 0.02% |
| Feb. 23, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | Snyder Mark Howard | SVP, GENERAL COUNSEL | A | Restricted Stock Units | 28045 | $0.00 | 28,045.0000 | 134,197,000 | 9999.99% | 0.02% |
| Feb. 16, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | Snyder Mark Howard | SVP, GENERAL COUNSEL | M | Restricted Stock Units | 4796 | $0.00 | 14,388.0000 | 134,197,000 | 25.00% | 0.00% |
| Feb. 16, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | Snyder Mark Howard | SVP, GENERAL COUNSEL | M | Common Stock | 4796 | $0.00 | 14,257.0000 | 134,197,000 | 50.69% | 0.00% |
| Feb. 16, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | Snyder Mark Howard | SVP, GENERAL COUNSEL | F | Common Stock | 2577 | $36.10 | 11,680.0000 | 134,197,000 | 18.08% | 0.00% |
| Jan. 3, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | Snyder Mark Howard | SVP, GENERAL COUNSEL | M | Restricted Stock Units | 7611 | $0.00 | 15,222.0000 | 134,197,000 | 33.33% | 0.01% |
| Jan. 3, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | Snyder Mark Howard | SVP, GENERAL COUNSEL | M | Common Stock | 7611 | $0.00 | 12,418.0000 | 134,197,000 | 158.33% | 0.01% |
| Jan. 3, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | Snyder Mark Howard | SVP, GENERAL COUNSEL | F | Common Stock | 2957 | $35.78 | 9,461.0000 | 134,197,000 | 23.81% | 0.00% |